METASTATIC PROSTATE CANCER

This large, late-stage trial is testing if a drug that helps prevent painful bone complications in people with metastatic breast or prostate cancer is just as effective when given every 12 weeks instead of the standard every 4 weeks. The goal is to see if the less frequent schedu…

This study is testing a combination of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in men with a rare, aggressive form of prostate cancer that has spread. The goal is to see if this intensive treatment can stop the cancer from growing for at least 6 months an…

This study is for men with advanced prostate cancer that has spread and is no longer responding well to standard hormone therapy. It compares a new two-drug combination (cabozantinib and atezolizumab) against a second round of standard hormone therapy. The main goals are to see i…

This study is testing whether adding a highly focused, high-dose radiation treatment to standard care helps people with breast, lung, or prostate cancer that has spread to only a few bones (1-5 sites). It aims to see if this combined approach can keep the cancer from getting wors…

This study is testing whether adding two oral drugs, darolutamide and abemaciclib, to standard hormone therapy is safe and effective for men with high-risk prostate cancer. The first part aims to find the best dose, and the second part would have compared the full combination to …

This early-stage study is testing a new drug called ST101 in patients with advanced solid tumors that cannot be surgically removed and have spread. The trial aims to find a safe and effective dose for cancers including glioblastoma, melanoma, breast cancer, and prostate cancer in…

This early-stage study is testing a new drug called AZD5305 when given alongside standard hormone therapies for men with metastatic prostate cancer. The main goals are to find a safe dose and see if the combination shows early signs of helping control the cancer. The study will e…

This is an early safety study testing a new drug called ARX517 for men with advanced prostate cancer that has spread. The study will see how safe the drug is when given alone or combined with other prostate cancer medications. Researchers will also check how the drug moves throug…

This study is testing a new type of imaging scan to see if it can better locate prostate cancer in the body. It is for men who have been newly diagnosed with high-risk cancer or whose cancer has returned after initial treatment. Participants receive an injection of a radioactive …

This study is testing whether a new type of imaging scan, called a PSMA PET scan, is more accurate than standard scans at showing how prostate cancer responds to treatment. Researchers will follow 58 men with progressive prostate cancer. The goal is to see if changes on these spe…

This study is testing if a new type of imaging scan can better detect prostate cancer that has spread to other parts of the body, like bones. Men with metastatic prostate cancer will get two different scans to compare their accuracy. The goal is to see if the new scan, which uses…

This study aims to find out which of two common prostate cancer medications—enzalutamide or darolutamide—has less impact on memory, concentration, and other thinking skills. About 111 men with advanced prostate cancer will take one of the drugs and complete regular computer-based…

This study aims to understand why prostate cancer eventually stops responding to standard hormone-blocking treatments. Researchers will analyze small tissue samples and blood from 30 patients with advanced prostate cancer before and during their hormone therapy. The goal is to fi…

This study is testing whether a type of advanced scan called PSMA-PET can be used to monitor how well treatment is working for men with metastatic prostate cancer that responds to hormone therapy. Twenty participants will receive standard treatment and undergo two of these scans—…